GENFIT Corp.: Gft505 Treatment Prevents Evolution To Cirrhosis
Lille (France), Boston (Massachusetts, United States), December 16, 2014 – GENFIT (Euronext: GNFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces that a recent study provides new evidence for anti-cirrhotic effects of GFT505 in the context of NASH.
The aim of NASH treatment is to eliminate the pathology responsible for the development of fibrosis, and to prevent disease evolution to cirrhosis and its complications. In the model used for this study (Wistar rats fed a choline-deficient L-amino acid-defined (CDAA) diet + 1% cholesterol for 11 weeks), NASH is associated with the development of marked hepatic fibrosis that can progress to cirrhosis.
In this study, one group was treated with GFT505 and the results compared to those of the control group. The efficacy of GFT505 on NASH was assessed according to the same diagnostic criteria applied to the ongoing Phase 2b clinical study (GFT505-212-7: GOLDEN-505). Fibrosis was evaluated according to the scale classically used in the clinic, from Stage 0 (no fibrosis) to Stage 4 (cirrhosis).
While 91% of the control group developed NASH, only 25% of the group treated with GFT505 had NASH at the end of the treatment period.
About GENFIT:
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in fields of high medical need due to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT’s R&D efforts are focused on contributing to bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). GENFIT implements mutually beneficial approaches that combine novel treatments and biomarkers; its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including GENFIT’s lead proprietary compound, GFT505, that is completing a Phase 2b study in NASH. With facilities in Lille, France, and Boston, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: GNFT; ISIN: FR0004163111). www.genfit.com
Help employers find you! Check out all the jobs and post your resume.
The aim of NASH treatment is to eliminate the pathology responsible for the development of fibrosis, and to prevent disease evolution to cirrhosis and its complications. In the model used for this study (Wistar rats fed a choline-deficient L-amino acid-defined (CDAA) diet + 1% cholesterol for 11 weeks), NASH is associated with the development of marked hepatic fibrosis that can progress to cirrhosis.
In this study, one group was treated with GFT505 and the results compared to those of the control group. The efficacy of GFT505 on NASH was assessed according to the same diagnostic criteria applied to the ongoing Phase 2b clinical study (GFT505-212-7: GOLDEN-505). Fibrosis was evaluated according to the scale classically used in the clinic, from Stage 0 (no fibrosis) to Stage 4 (cirrhosis).
While 91% of the control group developed NASH, only 25% of the group treated with GFT505 had NASH at the end of the treatment period.
About GENFIT:
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in fields of high medical need due to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT’s R&D efforts are focused on contributing to bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). GENFIT implements mutually beneficial approaches that combine novel treatments and biomarkers; its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including GENFIT’s lead proprietary compound, GFT505, that is completing a Phase 2b study in NASH. With facilities in Lille, France, and Boston, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: GNFT; ISIN: FR0004163111). www.genfit.com
Help employers find you! Check out all the jobs and post your resume.